psalexa
logo

PD-1 & PD-L1 Inhibitors Pipeline Analysis

Global Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025 – Industry Insights by Drug (Opdivo, Keytruda, Tecentriq, Durvalumab, Avelumab), by Mechanism of Action (PD-1 Inhibitor, PD-L1 Inhibitor)

Published: January 2017
Report Code: LS10752
Available Format:
Pages: 168

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Scope and Methodology

1.1 Market Definition

1.2 Research Scope

1.2.1 Market segmentation by drug

1.2.2 Market segmentation by mechanism of action (MoA)

1.3 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.2 Trends in the Global PD-1 & PD-L1 Inhibitors Market

3.3 Opportunities in the Global PD-1 & PD-L1 inhibitor market

3.4 Factors Driving Growth of the Market and its Impact on Market Forecast

3.5 Factors Hindering the Growth of the Market and its Impact on Market Forecast

Chapter 4. Global PD-1 & PD-L1 Inhibitors Pipeline Analysis

4.1 Overview

4.4.1 Pipeline Analysis by MOA

4.4.2 Pipeline Analysis by Molecule type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4  Pipeline Analysis by Company

Chapter 5. Global PD-1 & PD-L1 Inhibitors Pipeline Analysis by Phase (2016)

5.1 Filed: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase II: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Clinical Trials

5.3.4 Clinical Results

5.3.5 Strategic Development

5.3.6 Designation

5.3.7 Grants

5.3.8 Patent

5.3.9 Technology

5.4 Phase I: Drug profiles

5.4.1 Pre-Clinical Study

5.4.2 Pre-Clinical Results

5.4.3 Clinical Trials

5.4.4 Clinical Results

5.4.5 Strategic Development

5.4.6 Designation

5.4.7 Grants

5.4.8 Patent

5.4.9 Technology

5.5 Pre-Clinical: Drug profiles

5.5.1 Pre-Clinical Study

5.5.2 Pre-Clinical Results

5.5.3 Strategic Development

5.5.4 Designation

5.5.5 Grants

5.5.6 Patent

5.5.7 Technology

Chapter 6 Competitive Landscape

6.1 SWOT Analysis of PD-1 and PD-L1 Inhibitors

Chapter 7 Global PD-1 & PD-L1 Inhibitors Market Size and Forecast (2015 - 2025)

7.1 Global PD-1 & PD-L1 inhibitors Market, by Drug

7.2 Global PD-1 & PD-L1 Inhibitors Market, by Mechanism of Action (MoA)

Chapter 8 Global PD-1 & PD-L1 Inhibitors Market, by Drug

8.1 Opdivo (Nivolumab) Market

8.2 Keytruda (Pembrolizumab) Market

8.3 Tecentriq (Atezolizumab) Market

8.4 Durvalumab Market

8.5 Avelumab Market

Chapter 9. Global PD-1 & PD-L1 Inhibitors Market, by Mechanism of Action (MoA)

9.1 PD-1 Inhibitor Market

9.2 PD-L1 Inhibitor Market

Chapter 10. Competitive Analysis

10.1 Porter’s Five Forces of Competitive Position Analysis

10.2 Market Share Analysis of Key Players

Chapter 11. Company Profiles and Strategic Developments

Chapter 12. Appendix

LIST OF TABLES

SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SNAPSHOT

ANTI-PD-1 COMBINATIONS WITH MONOCLONAL ANTIBODIES OR OTHER IMMUNO-ONCOLOGY AGENTS

ANTI-PD-L1 COMBINATIONS WITH MONOCLONAL ANTIBODIES OR OTHER IMMUNO-ONCOLOGY AGENTS

ANTI PD-1 & PD-L1 MAB COMBINATIONS WITH VACCINES

ANTI PD-1 & PD-L1 MAB COMBINED WITH GENE AND CELL THERAPIES AND OTHER NOVEL APPROACHES

DIFFERENT DRUG DESIGNATION FOR PD-1 & PD-L1 INHIBITORS

DRIVERS FOR THE MARKET: IMPACT ANALYSIS

RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

PIPELINE ANALYSIS OF PD-1 & PD-L1 INHIBITORS, BY COMPANY (2016)

DESCRIPTION OF FILED DRUG CANDIDATES

CLINICAL TRIALS OF FILED DRUG CANDIDATES

DESCRIPTION OF PHASE III DRUG CANDIDATES

CLINICAL TRIALS OF PHASE III DRUG CANDIDATES

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

SWOT ANALYSIS OF BACE INHIBITORS PIPELINE

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2014 – 2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2017 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2014 – 2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2017 – 2025)

GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2014 – 2016)

GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2017 – 2025)

COMPANIES- AT A GLANCE

 

LIST OF FIGURES

RESEARCH SCOPE FOR GLOBAL PD-1 & PD-L1 INHIBITORS MARKET

RESEARCH METHODOLOGY FOR GLOBAL PD-1 & PD-L1 INHIBITORS MARKET

DEACTIVATED T CELL IN PD-1 AND PD-L1

ACTIVATED T CELL IN PD-1 AND PD-L1 INHIBITORS

GLOBAL DEATHS CAUSED BY CANCER (2012)

NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR PD-1 AND PD-L1 INHIBITORS (2016)

GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY MECHANISM OF ACTION (2016)

GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY MOLECULE TYPE (2016)

GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, $M (2014 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2014 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SPLIT, BY DRUG (2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2014 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SPLIT, BY MOA (2016)

GLOBAL OPDIVO MARKET, $M (2014 – 2025)

GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2014 – 2025)

GLOBAL OPDIVO MARKET SPLIT, BY COUNTRY (2016)

GLOBAL KEYTRUDA MARKET, $M (2014 – 2025)

GLOBAL TECENTRIQ MARKET, $M (2014 – 2025)

GLOBAL DURVALUMAB MARKET, $M (2014 – 2025)

GLOBAL AVELUMAB MARKET, $M (2014 – 2025)

GLOBAL PD-1 INHIBITOR MARKET, $M (2014 – 2025)

GLOBAL PD-L1 INHIBITOR MARKET, $M (2014 – 2025)

PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

MARKET SHARE ANALYSIS OF KEY PLAYERS (2016)

MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 6500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 7500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 10500

Pre-Purchase Enquiry